Abstract
Despite the fact that anti-TNF alpha antibodies are well-tolerated and highly effective in Crohns disease 25% to 40% of patients who initially benefited from the treatment are developing intolerable adverse events or are losing their response during maintenance therapy. The molecular mechanisms of loss of response are not fully understood, but clinicians face this clinical problem. The Aim of this paper is to review the clinical strategies to face loss of response to anti- TNF alpha antibodies in Crohns disease.
Current Drug Targets
Title: “How to Manage Loss of Response to Anti-TNF in Crohns Disease?”
Volume: 11 Issue: 2
Author(s): Walter Reinisch
Affiliation:
Abstract: Despite the fact that anti-TNF alpha antibodies are well-tolerated and highly effective in Crohns disease 25% to 40% of patients who initially benefited from the treatment are developing intolerable adverse events or are losing their response during maintenance therapy. The molecular mechanisms of loss of response are not fully understood, but clinicians face this clinical problem. The Aim of this paper is to review the clinical strategies to face loss of response to anti- TNF alpha antibodies in Crohns disease.
Export Options
About this article
Cite this article as:
Reinisch Walter, “How to Manage Loss of Response to Anti-TNF in Crohns Disease?”, Current Drug Targets 2010; 11 (2) . https://dx.doi.org/10.2174/138945010790309894
DOI https://dx.doi.org/10.2174/138945010790309894 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Flavonoids as Multi-Target Compounds in Drug Discovery
Mini-Reviews in Organic Chemistry Small Molecule Inhibitors of Lck: The Search for Specificity within a Kinase Family
Mini-Reviews in Medicinal Chemistry Proteomic Analysis of Plasma to Reveal the Impact of Short-Term Etanercept Therapy in Pediatric Patients with Enthesitis-Related Arthritis: A Case Report
Combinatorial Chemistry & High Throughput Screening Natural Marine Anti-inflammatory Products
Mini-Reviews in Medicinal Chemistry Affinity-Based Methods in Drug-Target Discovery
Current Drug Targets Cushing Syndrome and Giant Sterile Abscess Induced by Self Intramuscular Injection of Supra-therapeutic Doses of Triamcinolone
Drug Metabolism Letters The Use of n-3 Polyunsaturated Fatty Acids as Therapeutic Agents for Inflammatory Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Deciphering the Physiology Underlying the Rapid Clinical Effects of Perispinal Etanercept in Alzheimers Disease
Current Alzheimer Research Inflammation in Coronary Artery Disease and Acute Myocardial Infarction - is the Stage Set for Novel Therapies?
Current Pharmaceutical Design Novel Carriers for Controlled Site Specific Delivery of Anti-Inflammatory Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Effects of Hypoxia and Ischemia on MicroRNAs in the Brain
Current Medicinal Chemistry Chemokine Receptors as Specific Anti-Inflammatory Targets in Peripheral Nerves
Endocrine, Metabolic & Immune Disorders - Drug Targets Antigenicity Prediction in Melittin: Possibilities of in Drug Development from Apis dorsata
Current Proteomics The Involvement of TNF-α in Cognitive Dysfunction Associated with Major Depressive Disorder: An Opportunity for Domain Specific Treatments
Current Neuropharmacology Editorial [ Hot Topic: Current Drug Targets in Degenerative Joint Disease (Guest Editors: T. Aigner and E. Bartnik) ]
Current Drug Targets The Imaging of Apoptosis with the Radiolabelled Annexin A5: A New Tool in Translational Research
Current Clinical Pharmacology Anti-inflammatory Phytochemicals for Chemoprevention of Colon Cancer
Current Cancer Drug Targets Potential Targets for Anti-Inflammatory and Anti-Allergic Activities of Marine Algae: An Overview
Inflammation & Allergy - Drug Targets (Discontinued) Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases
Current Signal Transduction Therapy The Treatment of Wrist Osteoarthritis, SLAC Wrist Grade 3-4
Current Rheumatology Reviews